- Home
- UTHR vs EMA Comparison
UTHR vs EMA Comparison
Compare UTHR & EMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- EMA
- Stock Information
- Founded
- UTHR 1996
- EMA 1998
- Country
- UTHR United States
- EMA Canada
- Employees
- UTHR N/A
- EMA N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- EMA Electric Utilities: Central
- Sector
- UTHR Health Care
- EMA Utilities
- Exchange
- UTHR Nasdaq
- EMA Nasdaq
- Market Cap
- UTHR 13.8B
- EMA 13.6B
- IPO Year
- UTHR 1999
- EMA N/A
- Fundamental
- Price
- UTHR $312.23
- EMA $47.95
- Analyst Decision
- UTHR Buy
- EMA Hold
- Analyst Count
- UTHR 13
- EMA 1
- Target Price
- UTHR $382.00
- EMA $68.00
- AVG Volume (30 Days)
- UTHR 762.5K
- EMA 125.1K
- Earning Date
- UTHR 07-30-2025
- EMA 08-08-2025
- Dividend Yield
- UTHR N/A
- EMA 4.31%
- EPS Growth
- UTHR 17.94
- EMA 15.04
- EPS
- UTHR 25.63
- EMA 2.18
- Revenue
- UTHR $3,077,800,000.00
- EMA $6,033,610,485.00
- Revenue This Year
- UTHR $14.37
- EMA $21.04
- Revenue Next Year
- UTHR $6.59
- EMA N/A
- P/E Ratio
- UTHR $12.18
- EMA $22.35
- Revenue Growth
- UTHR 17.62
- EMA 12.01
- 52 Week Low
- UTHR $266.98
- EMA $43.90
- 52 Week High
- UTHR $417.82
- EMA $49.01
- Technical
- Relative Strength Index (RSI)
- UTHR 58.33
- EMA 58.70
- Support Level
- UTHR $303.59
- EMA $47.43
- Resistance Level
- UTHR $317.31
- EMA $48.39
- Average True Range (ATR)
- UTHR 7.91
- EMA 0.59
- MACD
- UTHR 0.90
- EMA -0.02
- Stochastic Oscillator
- UTHR 80.53
- EMA 50.23
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About EMA Emera Incorporated Common Shares
Emera is a geographically diverse energy and services company investing in electricity generation, transmission, and distribution as well as gas transmission and utility energy services. Emera has operations throughout North America and the Caribbean countries.